Ann Dermatol.  2019 Feb;31(1):103-105. 10.5021/ad.2019.31.1.103.

Pirfenidone-Induced Lichenoid Drug Eruption in a Patient with Idiopathic Lung Fibrosis

• Jeong IJ
• Lee HJ
• Yoon MS
• Kim DH

• KMID: 2430814
• DOI: http://doi.org/10.5021/ad.2019.31.1.103

Abstract

No abstract available.

MeSH Terms

Drug Eruptions*
Fibrosis*
Humans
Lung*

Figure

• 

  Fig. 1 Symmetrically distributed, multiple erythematous patches and papules with focal desquamation on the whole body.

• 

  Fig. 2 (A) Hyperkeratosis and upper-dermal cellular infiltration obscures the epidermo-dermal junction. In mid to deep dermis, inflammatory cells infiltrate around vessels (H&E, ×40). (B, C) Necrotizing keratinocytes in the epidermis. Note the melanophages and lymphocytes in the cellular infiltrates (H&E: B, ×200; C, ×400).

Reference

1. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377:1760–1769.

2. Jiang C, Huang H, Liu J, Wang Y, Lu Z, Xu Z. Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. PLoS One. 2012; 7:e47024.

3. Natkunarajah J, Stitson RN, Harland CC. A florid rash during summer. Photodistributed lichenoid drug eruption (LDE) secondary to quinine. Clin Exp Dermatol. 2010; 35:e83–e84.

4. Seto Y, Inoue R, Kato M, Yamada S, Onoue S. Photosafety assessments on pirfenidone: photochemical, photobiological, and pharmacokinetic characterization. J Photochem Photobiol B. 2013; 120:44–51.

5. Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol. 2009; 61:104–111.